Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Cited by (208)

Items 201–208 of 208

1. Prediabetes, Malignant Ventricular Hypertrophy and Stroke: The SPRINT Trial
   Arnaud D. Kazé, Stephen Paul Juraschek, Jordana B. Cohen, Siddharth Singh, Chiadi E. Ndumele, Christie Mitchell Ballantyne, Jarrett D. Berry, Justin Basile Echouffo-Tcheugui · 2026 · Diabetes Obesity and Metabolism
2. Practical Considerations for the Use of Oral Glucagon-like Peptide-1 Receptor Agonist in India
   Hamid Ashraf, Sanjeev Bakshi, Harshal Ekatpure, N S Praveen Kumar, Manodip Acharyya, Jakka Nagendar Reddy, Jayaditya Ghosh, Amith Goel, Ritesh Chaudhary, Ashish Saini et al. · 2026 · International Journal of Diabetes and Technology
3. Efficacy of Initiation of Semaglutide versus SGLT2 Inhibitors in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Propensity-Matched Real-World Study
   Ibrahim Khalil, Pallab Sarker, M Sahadat Hossain, Anika Chowdhury, Aizaz Anwar Khalid, Ananna Saha, Joydip Chowdhury, Mst. Mahmuda Akter, Sunjida Amin Promi, Md Abu Sayed et al. · 2026 · Endocrine Practice
4. Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults
   Anna Pendrey, Jennyfer Alejandra Rivera Sierra, Fernando Alberto Alvarez Lobo, Eblin Jackeline Ríos Herrera, Yolanda María Fernández Muñoz, Javier Sevilla‐Martir · 2026 · Advances in Therapy
5. Obese and overweight patients with type 2 diabetes mellitus are not treated optimally - an overview of current clinical practice and future perspectives
   Tanja Miličević, Ivna Cvitković, Špela Volčanšek, Niki Katsiki, Dimitri P. Mikhailidis, Dimitrios Patoulias, Emir M. Muzurović · 2026 · Expert Review of Clinical Pharmacology
6. Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity
   Paul S. Pagel, Dustin Hang, Julie K. Freed, George J. Crystal · 2026 · Journal of Cardiothoracic and Vascular Anesthesia
7. Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis
   Mohamed Gamal Hegaz, Mohammad Yassin Al Aboud, Abanoub I.I. Kamel, Muhammad Abdullah Naveed, Omar Gamal Elsayad, Aqsa Zoey Sorathia · 2026 · BMC Endocrine Disorders
8. Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study
   Muhammad Ali Ibrahim Kazi, Syed Musa Mufarrih, Akanksha Sirohi, Fahad Hasan, Akshay Sharma, Sanmeet Singh, Nargiz F Muganlinskaya, Nowreen Haq · 2026 · PLoS ONE